| UHC Surest Medical and Drug | Hemgenix® (Etranacogene Dezaparvovec-Drlb) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC Surest Medical and Drug | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC Surest Medical and Drug | Orencia® (Abatacept) Injection for Intravenous Infusion – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC Surest Medical and Drug | Oxlumo® (Lumasiran) and Rivfloza® (Nedosiran) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC Surest Medical and Drug | RNA-Targeted Therapies (Amvuttra® and Onpattro®) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC Surest Medical and Drug | Spevigo® (Spesolimab-Sbzo) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC Surest Medical and Drug | Trogarzo® (Ibalizumab-Uiyk) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Hemgenix® (Etranacogene Dezaparvovec-Drlb) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Orencia® (Abatacept) Injection for Intravenous Infusion – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-06-01 |